Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 6/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019562 | 0.92 | CHRNA7 (0.39) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL1018529 | 0.91 | CHRNA7 (0.40) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL1020853 | 0.87 | CHRNA7 (0.48) | CHRM1CHRM2CHRNA7 | |
| SCHEMBL1019631 | 0.86 | CHRNA7 (0.41) | CHRM1CHRM2CHRNA7 | |
| SCHEMBL1019699 | 0.71 | CHRNA7 (0.41) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL1542299 | 0.69 | LSS (0.55) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL7325360 | 0.68 | CHRM2 (0.55) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL3218491 | 0.68 | LSS (0.56) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL3218661 | 0.68 | LSS (0.56) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL3218495 | 0.68 | LSS (0.56) | CHRM1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802616-B1 | NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH AS (DK) | 2011-01-12 | — | — | EP | claimed |
| US-20100227869-A1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2010-09-09 | — | — | US | claimed |
| US-7652010-B2 | Azabicyclic aryl derivatives and their medical use | NEUROSEARCH A/S (DK) | 2010-01-26 | — | — | US | claimed |
| EP-1987029-B1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH AS (DK) | 2010-01-13 | — | — | EP | claimed |
| EP-1987029-A1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2008-11-05 | — | — | EP | claimed |
| US-20070299082-A1 | Novel Azabicyclic Aryl Derivatives and Their Medical Use | ANIONA APS (DK) | 2007-12-27 | — | — | US | claimed |
| WO-2007093602-A1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2007-08-23 | — | — | WO | claimed |
| EP-1802616-A1 | NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-07-04 | — | — | EP | claimed |
| WO-2006040352-A1 | NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-04-20 | — | — | WO | claimed |
| EP-1802616-B1 | NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH AS (DK) | 2011-01-12 | — | — | EP | disclosed |
| US-20100227869-A1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| US-7652010-B2 | Azabicyclic aryl derivatives and their medical use | NEUROSEARCH A/S (DK) | 2010-01-26 | — | — | US | disclosed |
| EP-1987029-B1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH AS (DK) | 2010-01-13 | — | — | EP | disclosed |
| EP-1987029-A1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2008-11-05 | — | — | EP | disclosed |
| US-20070299082-A1 | Novel Azabicyclic Aryl Derivatives and Their Medical Use | ANIONA APS (DK) | 2007-12-27 | — | — | US | disclosed |
| WO-2007093602-A1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2007-08-23 | — | — | WO | disclosed |
| EP-1802616-A1 | NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040352-A1 | NOVEL AZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299082-A1 | Novel Azabicyclic Aryl Derivatives and Their Medical Use | CHRNA6, CHRNA10, CHRNA5 | CHRM1 39/4885CHRM2 19/4885CHRM4 25/4885 |
| US-20100227869-A1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA5, CHRNA6, CHRNA2 | CHRM1 26/4885CHRM2 18/4885CHRM4 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.